|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | |
| C07K 16/30 | |||
| A61P 35/00 | |||
| A61K 47/68 |
| (11) | Number of the document | 3383909 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16819220.1 |
| Date of filing the European patent application | 2016-11-29 | |
| (97) | Date of publication of the European application | 2018-10-10 |
| (45) | Date of publication and mention of the grant of the patent | 2020-06-17 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/063990 |
| Date | 2016-11-29 |
| (87) | Number | WO 2017/095805 |
| Date | 2017-06-08 |
| (30) | Number | Date | Country code |
| 201562261092 P | 2015-11-30 | US | |
| 201662417480 P | 2016-11-04 | US |
| (72) |
GISH, Kurt C., US
HICKSON, Jonathan A., US
PURCELL, James W., US
MORGAN-LAPPE, Susan Elizabeth, US
|
| (73) |
AbbVie Inc.,
1 North Waukegan Road, North Chicago, IL 60064,
US
AbbVie Biotherapeutics Inc., 1500 Seaport Boulevard, Redwood City, CA 94063, US |
| (54) | ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |